Drugs / Ajmaline
Ajmaline
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02933437 | Oct 2017 → Dec 2019 | Brugada syndrome, sudden arrhythmia death syndrome | St George's, University of London | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00702117 | Jun 2008 → Jan 2010 | Brugada syndrome, atrial fibrillation, ventricular tachycardia | Hospital Clinic of Barcelona | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT02641431 Background | Nov 2015 → Dec 2016 | Brugada syndrome | IRCCS Policlinico S. Donato | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ajmaline | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02933437 ↗ |
| Known as | (17r,21r)-ajmalan-17,21-diol | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314404 ↗ |
| Known as | Ajmalan-17,21-diol | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314404 ↗ |
| Known as | NSC-15627 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314404 ↗ |
| Known as | Rauwolfine | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314404 ↗ |
| Modality | Small molecule | — CHEMBL5314404 ↗ |
| Route | Intravenous | “1 mg/kg iv in 10 minutes” NCT00702117 ↗ |